CH|EN
BHGB Announces China NMPA Acceptance for Review of the BLA for its Trivalent HPV Vaccine
2025-04-23
BHGB Announces its In-house Developed Trivalent HPV Vaccine is Granted Priority Review by the CDE 2025-03-21
BHGB and Chengda Bio Announce the Start of a Phase Ⅱ Clinical Trial of the Recombinant 15-valent HPV Vaccine 2025-03-19
BHGB Announces Positive Data Readout from Interim Analysis of the Phase Ⅲ Trial of Nonavalent HPV Vaccine in Females 2025-02-28
BHGB Receives DSMB’s Recommendation with Respect to the First Primary Endpoint Analysis in the Phase III Clinical Trial of its Nonavalent HPV Vaccine in Indonesia 2025-01-07
BHGB Holds 2024 Annual Meeting of Scientific Advisory Board in Beijing 2024-09-27
BHGB Announces Positive Data Readout from Interim Analysis of the Phase Ⅲ Trial of Trivalent HPV Vaccine 2024-08-13
BHGB Obtains Drug Manufacturing License 2024-08-05
BHGB Receives from the CSRC Notice of Regulatory Filing for Overseas Securities Offering and Listing 2024-07-11
BHGB Launches Technology Transfer for Nonavalent HPV Vaccine 2024-05-30
BHGB and Chengda Biotechnology Jointly Announce the Initiation of a PhaseⅠClinical Trial of the Recombinant 15-valent HPV vaccine 2024-03-29
More